Sarepta Therapeutics, Inc. $SRPT Stock Holdings Lowered by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC cut its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 77.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,945 shares of the biotechnology company’s stock after selling 37,928 shares during the period. Mutual of America Capital Management LLC’s holdings in Sarepta Therapeutics were worth $211,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. State of Michigan Retirement System increased its holdings in shares of Sarepta Therapeutics by 3.1% in the second quarter. State of Michigan Retirement System now owns 23,600 shares of the biotechnology company’s stock valued at $404,000 after buying an additional 700 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of Sarepta Therapeutics by 3.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock worth $396,000 after acquiring an additional 744 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Sarepta Therapeutics by 25.4% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,042 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 819 shares during the last quarter. New York Life Investment Management LLC raised its position in shares of Sarepta Therapeutics by 10.0% during the second quarter. New York Life Investment Management LLC now owns 10,623 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 966 shares during the period. Finally, Nordea Investment Management AB lifted its holdings in shares of Sarepta Therapeutics by 1.6% during the second quarter. Nordea Investment Management AB now owns 69,363 shares of the biotechnology company’s stock valued at $1,185,000 after purchasing an additional 1,066 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Stock Performance

SRPT stock opened at $18.50 on Friday. The firm has a 50 day simple moving average of $21.46 and a 200 day simple moving average of $19.96. Sarepta Therapeutics, Inc. has a 52 week low of $10.41 and a 52 week high of $114.41. The stock has a market cap of $1.94 billion, a P/E ratio of -6.15, a P/E/G ratio of 0.43 and a beta of 0.39. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.79 and a current ratio of 2.95.

Insider Activity

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of Sarepta Therapeutics stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total transaction of $294,201.97. Following the completion of the sale, the chief operating officer owned 193,300 shares of the company’s stock, valued at $4,312,523. This trade represents a 6.39% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 7.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on SRPT. Guggenheim decreased their price target on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Robert W. Baird reduced their price objective on shares of Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating for the company in a research note on Tuesday, November 4th. Barclays assumed coverage on shares of Sarepta Therapeutics in a report on Wednesday, January 28th. They issued an “equal weight” rating and a $20.00 target price for the company. Weiss Ratings restated a “sell (d)” rating on shares of Sarepta Therapeutics in a report on Monday, December 29th. Finally, Royal Bank Of Canada upped their price target on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the company a “sector perform” rating in a research report on Thursday, January 8th. Nine analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $33.84.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.